Featured Research

from universities, journals, and other organizations

15-year overall survival benefit lacking in older men treated with hormone therapy for early-stage prostate cancer

Date:
July 14, 2014
Source:
Rutgers Cancer Institute of New Jersey
Summary:
A popular prostate cancer treatment that disables male hormones known to promote growth of prostate cancer lacks survival benefit for older men with localized disease, a study concludes. The study focuses on ADT, which for the past 15 years has become a popular alternative to surgery, radiation or conservative management when used as the only therapy.

Research from investigators at Rutgers Cancer Institute of New Jersey shows a popular prostate cancer treatment that disables male hormones known to promote growth of prostate cancer lacks survival benefit for older men with localized disease. The study, "Fifteen-Year Survival Outcomes Following Primary Androgen Deprivation Therapy for Localized Prostate Cancer," focuses on this specific treatment (also known as ADT) which for the past 15 years has become a popular alternative to surgery, radiation or conservative management when used as the only therapy. The work appears in the latest edition of JAMA Internal Medicine.

The research utilized information from 66,717 Medicare patients aged 66 and older diagnosed with clinical stage T1-T2 prostate cancer (cancer that did not spread beyond the prostate) between 1992 and 2009. These men did not have surgery or radiation treatment within six months of their diagnosis. The data were compiled from the population-based Surveillance, Epidemiology, and End Results (SEER) database linked to Medicare files.

Grace Lu-Yao, PhD, MPH cancer epidemiologist at the Cancer Institute of New Jersey and professor of medicine at Rutgers Robert Wood Johnson Medical School, is the lead author. Previous research on ADT by her team with similarly aged men only followed patients until 2003. In this study, investigators extended the follow-up period by six years and included an additional 47,000 patients from different population areas covered by the SEER database. Median follow-up for overall survival was nine years.

In this new study, investigators found that when ADT was administered as the primary treatment for localized disease during the initial six month period following diagnosis, the hormone therapy was not associated with improved 15 year overall survival or prostate cancer-specific survival, especially among the majority of older men in the study group. This was compared to those patients who received no treatment of any type and instead underwent regular assessment -- a strategy known as 'conservative management.'

The study also showed little difference in survival rates between patient populations in areas of the country where ADT was more frequently used as a sole treatment versus areas where it was not. In both high- and low-use areas where ADT was used as the sole treatment, 15-year prostate cancer-specific survival was measured at 90.6 percent among patients with moderately differentiated cancer.

Dr. Lu-Yao notes that while previous research has shown ADT is appropriate for use in high-risk patients and in combination with other treatments, sole use -- especially in an older population -- should be carefully considered. "Because of the potential side effects of osteoporosis, diabetes and decreased muscle tone, clinicians must carefully consider the rationale behind ADT treatment if used as the primary therapy for older patients," she says. Lu-Yao adds as the data only included men 66 and older, results could differ for younger men.


Story Source:

The above story is based on materials provided by Rutgers Cancer Institute of New Jersey. Note: Materials may be edited for content and length.


Journal Reference:

  1. Grace L. Lu-Yao, Peter C. Albertsen, Dirk F. Moore, Weichung Shih, Yong Lin, Robert S. DiPaola, Siu-Long Yao. Fifteen-Year Survival Outcomes Following Primary Androgen-Deprivation Therapy for Localized Prostate Cancer. JAMA Internal Medicine, 2014; DOI: 10.1001/jamainternmed.2014.3028

Cite This Page:

Rutgers Cancer Institute of New Jersey. "15-year overall survival benefit lacking in older men treated with hormone therapy for early-stage prostate cancer." ScienceDaily. ScienceDaily, 14 July 2014. <www.sciencedaily.com/releases/2014/07/140714181915.htm>.
Rutgers Cancer Institute of New Jersey. (2014, July 14). 15-year overall survival benefit lacking in older men treated with hormone therapy for early-stage prostate cancer. ScienceDaily. Retrieved September 17, 2014 from www.sciencedaily.com/releases/2014/07/140714181915.htm
Rutgers Cancer Institute of New Jersey. "15-year overall survival benefit lacking in older men treated with hormone therapy for early-stage prostate cancer." ScienceDaily. www.sciencedaily.com/releases/2014/07/140714181915.htm (accessed September 17, 2014).

Share This



More Health & Medicine News

Wednesday, September 17, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Obesity Rates Steady Even As Americans' Waistlines Expand

Obesity Rates Steady Even As Americans' Waistlines Expand

Newsy (Sep. 17, 2014) Researchers are puzzled as to why obesity rates remain relatively stable as average waistlines continue to expand. Video provided by Newsy
Powered by NewsLook.com
President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com
Obama Orders Military Response to Ebola

Obama Orders Military Response to Ebola

AP (Sep. 16, 2014) Calling the Ebola outbreak in West Africa a potential threat to global security, President Barack Obama is ordering 3,000 U.S. military personnel to the stricken region amid worries that the outbreak is spiraling out of control. (Sept. 16) Video provided by AP
Powered by NewsLook.com
UN: 20,000 Could Be Infected With Ebola by Year End

UN: 20,000 Could Be Infected With Ebola by Year End

AFP (Sep. 16, 2014) Nearly $1.0 billion dollars is needed to fight the Ebola outbreak raging in west Africa, the United Nations say, warning that 20,000 could be infected by year end. Duration: 00:40 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins